Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Shaperon
Deal Size : Inapplicable
Deal Type : Inapplicable
Hudson Therapeutics Starts Phase 2b Trial for NuGel
Details : NuGel, a first-in-class topical inflammasome inhibitor, which is being evaluated for the treatment of mild to moderate atopic dermatitis.
Product Name : NuGel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Shaperon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shaperon Enrolls First Patient in Phase 2 U.S. Trial for Atopic Dermatitis Therapy 'Nugel'
Details : NuGel® is a gel type atopic dermatitis drug candidate, inhibiting NLRP3 inflammasome through GPCR19-P2X7 modulation. Its active pharmaceutical ingredient called HY209.
Product Name : Nugel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2020
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of HY209 in Healthy Male Volunteers for Sepsis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2020
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2018
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable